1589522-46-2 Usage
Uses
Used in Bioconjugation and Drug Synthesis:
Propargyl-PEG5-amine is used as a bioconjugation agent for the selective and efficient attachment of various biomolecules, such as proteins, peptides, and nucleic acids. The propargyl group facilitates the formation of stable triazole linkages through Click Chemistry, while the amine group allows for further functionalization and modification of the conjugated biomolecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Propargyl-PEG5-amine is employed as a component in the design and synthesis of drug delivery systems. The PEG spacer improves the solubility and stability of drug molecules, while the propargyl and amine moieties enable the attachment of therapeutic agents and targeting ligands, respectively. This results in enhanced bioavailability, targeted delivery, and reduced side effects for various drugs.
Used in Diagnostics and Imaging:
Propargyl-PEG5-amine is also utilized in the development of diagnostic and imaging agents. The propargyl group can be used to attach imaging labels or contrast agents to biomolecules, while the amine group can be employed for the attachment of recognition elements, such as antibodies or aptamers. This allows for the specific detection and visualization of various biological targets, including cancer cells, pathogens, and disease markers.
Used in Material Science:
In the field of material science, Propargyl-PEG5-amine is used as a building block for the synthesis of functional polymers and materials. The propargyl and amine moieties can be employed to create a variety of polymer architectures, such as block copolymers, star polymers, and dendrimers, with tailored properties and applications. These materials can be used in various applications, including drug delivery, tissue engineering, and sensing.
Check Digit Verification of cas no
The CAS Registry Mumber 1589522-46-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,8,9,5,2 and 2 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1589522-46:
(9*1)+(8*5)+(7*8)+(6*9)+(5*5)+(4*2)+(3*2)+(2*4)+(1*6)=212
212 % 10 = 2
So 1589522-46-2 is a valid CAS Registry Number.
1589522-46-2Relevant academic research and scientific papers
HETEROCYCLIC DERIVATIVES
-
, (2020/08/13)
Compounds of the formula (I): Q1-Q2-Q3, in which Q1, Q2 and Q3 have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.
RAF-DEGRADING CONJUGATE COMPOUNDS
-
Paragraph 0209; 0381-0382; 0391, (2018/11/22)
The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF- Degrading Conjugate Compound.
A modular approach to triazole-containing chemical inducers of dimerisation for yeast three-hybrid screening
Tran, Fanny,Odell, Anahi V.,Ward, Gary E.,Westwood, Nicholas J.
, p. 11639 - 11657 (2013/10/22)
The yeast three-hybrid (Y3H) approach shows considerable promise for the unbiased identification of novel small molecule-protein interactions. In recent years, it has been successfully used to link a number of bioactive molecules to novel protein binding partners. However despite its potential importance as a protein target identification method, the Y3H technique has not yet been widely adopted, in part due to the challenges associated with the synthesis of the complex chemical inducers of dimerisation (CIDs). The development of a modular approach using potentially "off the shelf" synthetic components was achieved and allowed the synthesis of a family of four triazole-containing CIDs, MTX-Cmpd2.2-2.5. These CIDs were then compared using the Y3H approach with three of them giving a strong positive interaction with a known target of compound 2, TgCDPK1. These results showed that the modular nature of our synthetic strategy may help to overcome the challenges currently encountered with CID synthesis and should contribute to the Y3H approach reaching its full potential as an unbiased target identification strategy.
